The FDA has approved datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancer who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback